|
Hormone
|
Treatment
|
n
|
0
|
1
|
1.5
|
2
|
2.5
|
Average
|
|---|
|
Vehicle
|
Saline
|
6
|
6
| | | | |
0.0
|
|
DOX
|
7
| | |
4
|
1
|
2
|
1.9
|
|
E2
|
Saline
|
7
|
7
| | | | |
0.0
|
|
DOX
|
7
| |
3
|
2
|
2
| |
1.4
|
|
E2 + P4
|
Saline
|
7
|
7
| | | | |
0.0
|
|
DOX
|
7
|
1
|
2
|
3
|
1
| |
1.2
|
|
E2 + Tam
|
Saline
|
7
|
7
| | | | |
0.0
|
|
DOX
|
7
| | |
4
|
2
|
1
|
1.8
|
|
Tam
|
Saline
|
7
|
7
| | | | |
0.0
|
|
DOX
|
7
| | |
3
|
1
|
3
|
2.0
|
|
P4
|
Saline
|
7
|
7
| | | | |
0.0
|
|
DOX
|
7
|
1
|
1
|
4
|
1
| |
1.3
|
- Histopathology of cardiac sections from the ovariectomized SHRs at day 12 was assessed for cardiomyocyte lesions (myofibrillar loss and vacuolization) by a board-certified pathologist. The cardiomyopathy or lesion score indicates the percentage of affected cardiomyocytes within the sampled heart section: 0 is no observed change, 1 is < 5%, 1.5 is 5–15%, 2 is 16–25%, 2.5 is 26–35%, and 3 is > 35%
